Advanced Analytics. Intelligent Insights.

IXICO helps pharmaceutical and biotech clients to get more from their clinical development programmes

logo-outline

IXICO's CEO Giulio Cerroni to present at Shares, Cenkos Growth & Innovation Forum

Our CEO, Giulio Cerroni will be presenting at next week's Growth & Innovation Forum, taking place at the Business Design Centre in London N1 on Tuesday 11th February. Giulio will be presenting in the Flower Room at 12. 15.

READ MORE

BGF investment fund's Paul Stevens: IXICO has “market leading position" & “impressive commercial traction”

The comments were made during the following Q&A session with Paul Stevens from BGF’s investment fund, who focuses on identifying opportunities among AIM-listed companies: 1. Can you provide some background on BGF and the sectors/types of companies you invest in?BGF was set up in 2011 to help support small growing companies in the UK.

READ MORE

Human Amyloid Imaging (HAI) Poster 2020

The Impact of Automatic Tau PET Processing On Uptake Variability and Power Analysis in AD

READ MORE

SCOPE Summit for Clinical Ops Executives

Over the course of four stimulating days of in-depth discussions in 20 different conferences, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Artificial Intelligence, Clinical...

READ MORE

Quality Assurance Coordinator

READ MORE

Consultancy

IXICO has extensive experience in supporting regulatory-compliant clinical research, working with clients on the selection and use of neuroimaging and digital biomarkers - whether directly with your teams or as part of collaborative consortia.

Read more

Early Phase

We have extensive experience in definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.


Read more

Late Phase

IXICO's global network of over 2,000 imaging sites across 75 countries and bespoke TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.

Read more

Post-Marketing

IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilization for ongoing optimization of patient pathways post marketing.

Read more

The diseases we work on include:

Alzheimer's Disease (AD)

IXICO has supported important Alzheimer's Disease research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies. We have provided both MRI and PET imaging biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.

Read more

Huntington's Disease (HD)

IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.

Read more

Parkinson's Disease (PD)

IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.

Read more

Multiple Sclerosis (MS)

We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.

Read more

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.

Read more

Other Rare Neurological Diseases

IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).

Read more
White arrow

01

Scanner icon 2

Imaging Biomarkers

Scanner icon 2

Imaging Biomarkers

IXICO is at the forefront of the industry in developing and validating unique neuroimaging methods and MRI and PET image analysis techniques, providing more accurate and richer brain structural and functional information.

Grey arrow

02

Digital Brain icon 2

Digital Biomarkers

Digital Brain icon 2

Digital Biomarkers

IXICO is developing and validating new machine learning algorithms to analyse wearable biosensor data for specific neurodegenerative diseases. These disease-specific algorithms can improve the sensitivity and specificity of standard algorithms to measure physiological parameters such as sleep, activity and circadian rhythm.

White arrow

03

AI icon 2

Analytics & AI

AI icon 2

Analytics & AI

In neuroscience, AI has applications across the spectrum of understanding and treating the disease. IXICO provides sophisticated AI technology to support clinical development programmes in interpreting complex patient data.

Grey arrow

04

Data platforms icon 2

Data Platforms

Data platforms icon 2

Data Platforms

IXICO's compliant image and digital data management, provides all you need to manage the complex data workflows that come with many clinical trials. IXICO also offers a secure online digital platform as an enabler of clinical decision support for patient selection and post-marketing surveillance.

Subscribe to our mailing list